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 Acute Respiratory Distress Syndrome (ARDS) is a clinical syndrome of multiple 
etiologies that leads to widespread alveolar inflammation, hyaline membrane formation 
and noncompliant lungs. ARDS remains underdiagnosed and undertreated with a high 
mortality rate in high and low income countries. There are limited treatment options for 
ARDS, including protective lung ventilation, fluid management, prone positioning and 
ECMO, which may not be used for a patient if they are not diagnosed correctly with 
ARDS. ARDS is underdiagnosed in low income countries due to the lack of resources, 
and the resulting lack of access to invasive tools used in the current gold standard 
diagnostic criteria for ARDS, the Berlin Criteria. To address this issue, Riviello and 
colleagues introduced the Kigali criteria, that diagnose ARDS using noninvasive tools 
which are available in low income nations. Vercesi and colleagues examined the Kigali 
criteria in ICU patients in the Netherlands and found a strong specificity when using 
stricter Lung Ultrasound criteria. The purpose of this study is to validate the utilization of 
the Kigali criteria in the early diagnosis of ARDS, with the use of echocardiography, 
physical exam findings, strict lung ultrasound criteria, and SpO2/FiO2 in screening 
patients on arrival to Emergency Departments and repeatedly during admission to 7 
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Acute Respiratory Distress Syndrome (ARDS) is a clinical syndrome defined by an acute 
onset of respiratory distress characterized by diffuse pulmonary infiltrates on imaging, 
not entirely attributed to left heart failure.1,2 Over the past 20 years, the epidemiology of 
ARDS has varied based on the criteria used to define it.3 Prior to the development of the 
American-European Consensus Conference (AECC) criteria in 1994, there was no 
consolidated definition for ARDS. The AECC ARDS criteria provided the first such 
definition allowing ARDS patients to be diagnosed and, thereby, enabling standardization 
for clinical trials. However, due to the inability of the AECC ARDS criteria to reliably 
diagnose ARDS in patients that later exhibited the pathological hallmarks of ARDS upon 
autopsy, the Berlin definition was introduced in 2012.2 The Berlin definition attempted to 
decrease physician subjectivity by standardizing ARDS symptoms, like the timeframe for 
the acuity of onset, the imaging findings on either chest radiograph or computed 
tomography (CT), the standard PaO2/FiO2 ratios, adding a standard minimum qualifying 
Positive End-Expiratory Pressure (PEEP) of 5cmH2O, and removing of the Pulmonary 
Capillary Wedge Pressure (PCWP).2 The PaO2 value is a measurement of the partial 
pressure of oxygen in the arterial blood, which is measured directly by arterial sampling. 
The FiO2 measurement represents the fraction of oxygen in the inspired air, which is 
0.21. PEEP represents the pressure maintained in the lungs after a full expiration. PCWP 
is an estimate of left atrial pressure, which is measured by a right heart catheter placed in 
a pulmonary artery. PCWP was used in the AECC criteria to rule out a cardiac etiology 
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as the cause of pulmonary edema. Since 2012, the Berlin definition has been regarded as 
the gold standard diagnostic and stratification tool for ARDS and is used for selecting 
patients for inclusion in ARDS clinical trials. 
 There is a proposed modified definition for ARDS, the Kigali modification, that 
uses noninvasive tools, such as ultrasound and echocardiography (ECHO), which could 
potentially be utilized in resource-constrained locations. The use of ultrasound has 
transformed the practice of critical care, enabling the clinician to obtain crucial clinical 
data noninvasively at the patient’s bedside. Ultrasound can be used in resource-
constrained settings that do not have access to radiology or invasive measurements, such 
as chest radiography, CT, right heart catheterization and arterial catheters, and, thus, its 
use would provide a benefit in providing objective measurements to clinicians, allowing 
them to make informed decisions in clinical management. Lichtenstein and colleagues 
developed the “Bedside Lung Ultrasound in Emergency” (BLUE) protocol, an algorithm 
that evaluates lung ultrasound profiles and provides highly accurate data for use in 
diagnosing an array of pulmonary syndromes.4 Some recent developments have 
demonstrated promising results for noninvasive bedside examination of patients, the 
BLUE protocol, used for diagnosing specific pulmonary syndromes, and the American 
Society of Echocardiography (ASE) protocol, used to determine left sided filling 
pressures in the heart. The combination of these protocols may be beneficial in providing 




Statement of the Problem 
Over the past 20 years, the epidemiology of ARDS has differed based on the location of 
the study and the criteria used for diagnosis. Incidence has varied from 10.1 to 86.2 cases 
per 100,000 person-years using the AECC and the Berlin criteria.6 The global estimation 
of the current incidence of ARDS is difficult to predict across nations.7 Many clinical 
trials take place in well-developed nations that have access to the imaging and invasive 
measures necessary to determine ARDS using the Berlin definition. Thus, ARDS is 
largely underrecognized in low-income nations because they lack the resources required 
to perform diagnostic tests.8  
 In 2014, Riviello and colleagues developed the Kigali criteria, a modified ARDS 
definition requiring less invasive diagnostic tools, for use in lower income populations. 
This criteria uses oxygen saturation probes for measuring SpO2 in place of arterial 
samples and lung ultrasound in place of CT.8 SpO2 is a measurement of blood oxygen 
saturation, the percent of hemoglobin molecules saturated with oxygen.9 More 
specifically, they performed a prospective observational study that incorporated 
SpO2/FiO2 in place of PaO2/FiO2, added lung ultrasound to chest radiograph in place of 
CT, removed a minimum PEEP value, and compared the results to the gold standard, 
Berlin definition.8 They found a differing incidence between the Kigali modification and 
the Berlin criteria due to limited access to invasive tools and chest radiograph in Rwanda.  
 In 2018, Vercesi and colleagues performed a follow up study, examining the 
diagnostic accuracy of the Kigali modification compared to the Berlin criteria.10 In this 
study, they included analysis of multiple changes to the Kigali criteria compared to the 
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Berlin criteria.10 One change applied a stricter lung ultrasound (LUS) criteria that 
required more lung zones to have imaging findings consistent with ARDS for a positive 
diagnosis, which improved the diagnostic accuracy of the Kigali criteria.10   
 There are many limitations in the Kigali modification, including the possible 
inclusion of cardiogenic pulmonary edema. The Kigali criteria requires an objective 
measurement using echocardiography (ECHO) to rule out hydrostatic edema fully 
explained by cardiac failure.8 The Kigali criteria also fails to specify the standards used to 
rule out cardiac etiology beyond a patient’s history of a myocardial infarction (MI) or 
heart failure in the chart and/or using ECHO to rule out valvular pathology.8  
 Lastly, there is a paucity of research examining the time from a patient’s 
presentation to the emergency department to the diagnosis of ARDS. The timing of 
ARDS onset from the patient’s admission to the hospital floor and the Intensive Care 
Unit (ICU) has been found to be associated with disease severity and outcome. Late onset 
of ARDS, generally defined as >48 hours from admission, is associated with a poorer 
prognosis and greater disease severity than earlier onset.11 The timing of ARDS onset and 
therapeutic intervention have become independent prognostic factors in the clinical 
outcome.11 Early institution of protective lung ventilation improves the outcome of 
ARDS and is the cornerstone of therapy.12,13 Other strategies in lung ventilation, 
including airway pressure release ventilation (APRV), have been explored in the early 
management of ARDS14 with early application of APRV resulting in improved 
oxygenation, respiratory system compliance, fewer days in the ICU, and lower duration 
on mechanical ventilation.12 
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With the introduction of the Kigali Modification, which uses noninvasive 
measurements, ARDS may be diagnosed sooner, allowing for triage to protective 
ventilation strategies and extracorporeal membrane oxygenation (ECMO). These 
interventions have proven beneficial if introduced early in the disease course.15 The 
modified Kigali protocol may also be applicable in low-income areas in which patients 
have limited treatment options, enabling them to be screened, diagnosed and transported 
to an institution with mechanical ventilation earlier in the disease course.  
Hypothesis 
The use of the modified Kigali definition incorporating tissue doppler and lung 
ultrasound will lead to an earlier diagnosis of ARDS when compared to the Berlin 
criteria. 
Objectives and specific aims 
Because evidence suggests patients benefit from earlier administration of protective lung 
ventilation strategies and ARDS remains largely underdiagnosed in resource-constrained 
settings, the objective of this study is to evaluate the time to diagnosis and the diagnostic 
accuracy of the modified Kigali definition when compared to the Berlin Criteria. Specific 
aims include: 
• To compare the time to diagnosis of ARDS with the modified Kigali criteria with 
the gold standard Berlin definition 
• To determine the diagnostic accuracy of the modified Kigali criteria compared to 




REVIEW OF THE LITERATURE 
Overview 
Pathophysiology of acute respiratory distress syndrome 
 Acute respiratory distress syndrome (ARDS) is clinically defined as a syndrome 
consisting of multiple etiologies that manifest as an acute inflammatory lung injury, 
which causes increased pulmonary vascular permeability.1 Increased permeability leads 
to increased flooding of the interstitial and alveolar spaces, loss of aerated lung tissue, 
and Ventilation/Perfusion (V/Q) mismatch reflected by systemic hypoxemia.2  
 Over the past 50 years, progress has been made in understanding the 
pathophysiological processes underlying this clinical syndrome in animal and human 
studies. The pathophysiology of ARDS is divided into 3 phases: (1) Exudative; (2) 
Proliferative; and (3) Fibrotic.1 
Exudative Phase  
The exudative phase is characterized by initial acute lung injury followed by the 
influx of protein concentrated fluid into the intra-alveolar spaces within the lung, and the 
interstitial space between the alveoli and microvasculature.2  
 The first steps in the exudative phase often begin within 24 hours of the initial 
lung injury.16 The source of injury may be either from a direct source (i.e., direct 
extension from the lung, such as pneumonia) or from an indirect source (i.e., extension 
from a systemic source, such as sepsis or a burn injury).16 Injury can lead to the 
destruction of susceptible tissues and zones in the lungs, including the alveolar epithelial 
tissue, the endothelial membrane, and the microvascular tissue that delivers oxygen to the 
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lungs.16 Damage to any of these tissues leads to cell membrane disruption shown by the 
local increase of intracellular markers, i.e., DNA and RNA, that are collectively referred 
to as Danger Associated Molecular Patterns (DAMPs).16 If the source of injury is 
infectious, there will likely be an increased presence of foreign pathogen markers, such as 
Pathogen Associated Molecular Patterns (PAMPs) that are specific to different bacterial 
pathogens.16 The local increases in PAMPs and DAMPs activate the innate immune 
system, including alveolar macrophages in the lung and the complement cascade in the 
systemic circulation.16,17 Activation of the alveolar macrophages transforms their function 
to an M1 activation state, a hyperinflammatory state characterized by the release of 
proinflammatory cytokines.16 This exacerbates the diffuse alveolar inflammation, leading 
to the recruitment of inflammatory cells, including neutrophils.16  
 Neutrophils release pro-inflammatory mediators that worsen local destruction of 
the alveolar epithelial-endothelial barrier, the barrier between the lungs and the 
microvasculature.16,17,18 The localized proliferation of the inflammatory mediators 
involved in this process ultimately leads to the breakdown of this barrier, which allows 
the escape of proteinaceous fluid into the intra-alveolar and interstitial spaces.16,17  
Epithelial and endothelial cell expression of TNFa, a protein involved in 
inflammation, leads to the development of proteinaceous hyaline membranes, a 
pathological hallmark of ARDS, first described by Katzenstein as diffuse alveolar 
damage (DAD).19 DAD is characterized by injury to the barrier between the alveoli and 
the vasculature, increased fluid in the intra-alveolar space, and the presence of protein 




The proliferative phase begins within 3 days of the initial injury and marks the 
beginning of the reparative process. The objective of this phase focuses on lung 
restoration and recovery.1 It is manifested by the appearance of cells involved in the 
reparative process, including fibroblasts, fibrocytes, myofibroblasts, and pluripotent 
mesenchymal progenitor cells that all function to rebuild the basement membrane.18 
During this time, the alveolar macrophages transform into a reparative M2 state to aid in 
the clearance of inflammatory debris.17 Additionally, Type II cells differentiate into Type 
I cells to restore tight junctions and, subsequently, decrease the extravasation of 
proteinaceous fluid into the lung.17 At this time, Type II cells restore the synthesis of 
surfactant, a lipoprotein complex that aids in lung function and compliance.1  
Fibrotic Phase 
The fibrotic phase occurs in the subset of patients with the most severe initial 
alveolar membrane damage.1 The body’s inability to repair the excessive damage in the 
lung leads to an elevated, robust response during the fibroproliferative phase, causing a 
profibrotic shift that leads to long term fibrosis.16,18 These patients are known to have an 
increased duration of mechanical ventilation and higher mortality.1  
 
Epidemiology/Incidence 
Through the advancement of critical care interventions and the incorporation of 
protective lung ventilation, the estimated incidence and mortality of ARDS have 
decreased in the United States over the past 20 years.3 In addition to the advancement of 
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critical care interventions that allow better treatment of the underlying conditions causing 
ARDS, the decrease in mortality is largely attributed to the protective lung ventilation 
strategy made possible by the standardization of its definition in clinical trials.3 
The global impact and incidence of ARDS is difficult to estimate with the bulk of 
epidemiological studies conducted predominating in developed countries. Even in 
developed nations, the estimates for incidence have varied from 10.1 to 86.2 cases per 
100,000 person-years over the past 20 years due to differences in the AECC and the 
Berlin criteria.6,20 In the most recent large international epidemiological study 
(LUNGSAFE trial), 29,144 patients from 459 ICUs from 50 countries were examined 
and it was found that ARDS accounted for 10.4% of ICU admissions with 23.4% of 
patients requiring mechanical ventilation.21 Also, the hospital mortality rate was 34.9%, 
40.3%, and 46.1% for mild, moderate, and severe ARDS, respectively. Additionally, it 
was found that, despite access to resources, ARDS remained underdiagnosed and 
undertreated with clinician recognition ranging from 51.3% for mild cases to 78.5% in 
severe cases with underutilization of the lung protective ventilation strategy.21 
In resource-constrained settings, which have limited access to mechanical 
ventilators and invasive technology to measure PCWPs and PaO2/FiO2 ratios, ARDS is 
likely underdiagnosed due to the inability to measure these parameters.1,20 For example, 
in a study examining the impact of ARDS in Rwanda, no cases of ARDS were diagnosed, 
probably due to the limited resources leading to an inability to apply the Berlin definition. 
However, 4 cases per 100,000 person-years were diagnosed with a 50% mortality rate 




Because ARDS is such a heterogenous disease, there are multiple etiologies that 
can be classified as: (1) Direct (local) and (2) Indirect (systemic).1 In recent 
epidemiological studies, pneumonia, aspiration of gastric contents, and sepsis accounted 
for 85% of the cases of ARDS1, however, etiologies vary based on global region. An 
observational prospective study in India found the main etiologies to be malaria (27.6%), 
leptospirosis (20.7%), undiagnosed fever (27.6%), and pneumonia (13.8%), which is 
dissimilar to the United States.22 
 
Diagnosis 
Historically, the term “acute respiratory distress syndrome” was first coined by 
Ashbaugh and colleagues.23 They recognized a clinical parallel between the signs and 
symptoms of the 12 patients they were treating and neonatal respiratory distress 
syndrome.23,24 They noted decreased lung compliance, tachypnea, a large alveolar-arterial 
oxygen tension difference, radiological changes, and, eventually, changes in autopsy 
findings showing heavy lungs, alveolar debris, and hyaline membrane formation.3,19 
These findings were later defined as diffuse alveolar damage (DAD), the pathological 
hallmark of this syndrome described by Katzenstein.3,19  
For more than 20 years, clinicians lacked gold-standard criteria to diagnose 
ARDS premortem, leaving the epidemiology, incidence, mortality and incorporation of 
treatment strategies from randomized controlled trials and observational studies difficult 
to gauge and translate into clinical practice. For example, mortality rates ranged from 10 
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to 90% over the past 20 years, making it difficult for clinicians to estimate prognosis with 
a given clinical presentation.25 In an attempt to stratify patients based on severity of 
parenchymal lung injury, Murray and colleagues proposed the incorporation of the lung 
injury score.26 The lung injury score functioned as a stratification tool and included 
PEEP, respiratory system compliance, degree of hypoxemia measured by PaO2/FiO2 
ratios, and chest radiograph to subcategorize patients based on severity of lung injury for 
the inclusion in clinical trials.26 In 1994, the American Thoracic Society and European 
Society of Intensive Care Medicine created the first uniform definition of ARDS, the 
AECC criteria, standardizing the diagnosis of ARDS that would ultimately become the 
foundation for the inclusion criteria in epidemiological and therapeutic intervention 
studies in subsequent years.3  
The AECC criteria consisted of 4 categories: timing, hypoxemia, imaging and 
cardiac exclusion (Table 1).27 The AECC criteria categorized severity of lung injury 
based on degree of hypoxemia, distinguishing ARDS with a PaO2/FiO2 ≤200mmHg, 
from Acute Lung Injury (ALI) that had a similar underlying pathophysiology but less 









Table 1. AECC Criteria used to Diagnose ARDS Introduced in 1994 
Timing Acute and sudden onset 
Hypoxemia ALI: >200mmHg PaO2/FiO2 ≤300 mmHg 
ARDS: PaO2/FiO2 ≤200mmHg 
(regardless of PEEP) 
Imaging Diffuse bilateral infiltrates on chest radiograph 
Cardiac Exclusion Absence of left atrial hypertension, PCWP 
≤18mmHg when measured or no clinical 
evidence of left heart failure 
ALI: Acute Lung Injury 
ARDS: Acute Respiratory Distress Syndrome 
PEEP: Pulmonary End Expiratory Pressure 
PCWP: Pulmonary Capillary Wedge Pressure 
 
 
Although the AECC criteria condensed the constellation of clinical, radiological, 
and physical abnormalities into a single definition for ARDS, over time, its diagnostic 
accuracy was questioned. Criticisms of the criteria included insufficient validity and 
reliability and an inability to segregate patients based on severity of illness into more 
homogenous groups for entrance into studies.28  For instance, the AECC criteria lacked a 
specific timeframe for the onset of symptoms, leaving clinicians to set deadlines based on 
personal discretion.3 The oxygenation status was suboptimal in differentiating patients 
based on severity of lung injury, leading to clinical variation within subgroups submitted 
for trials.2 The difference in titles based on hypoxemia, i.e., ALI vs ARDS, led to the 
inaccurate perception that they were completely separate diagnoses despite their common 
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underlying pathophysiology.28 The incorporation of PEEP was considered but, ultimately, 
avoided due to varying physician practice patterns and clinical settings without access to 
mechanical ventilation, which would contribute to inaccurate classification.27 For 
example, it was noted that, in severe cases of ARDS, mechanical ventilation may not be 
utilized based on the patient’s wishes or the physician’s opinion that it would be futile, 
therefore, underestimating the severity of lung injury in these patients.27  
The imaging criteria in the AECC definition also lacked explicit clarity on the 
requirements for a positive finding.28 Chest radiographs, the imaging modality specified 
in the definition, have demonstrated a wide interobserver variability and lack of 
sensitivity, requiring extravascular lung water (EVLW), a marker of pulmonary edema, to 
be at least 35% above normal for recognition.29,30,31 Lichtenstein and colleagues 
examined chest radiograph diagnostic accuracy in comparison to auscultation and lung 
ultrasound and found the diagnostic accuracy of chest radiograph for pleural effusion 
(47%), alveolar consolidation (75%), and alveolar interstitial syndrome (72%) was lower 
than that of ultrasound at 93%, 97%, and 95%, respectively.32  
The presence of PCWP ≤18mmHg in the criteria for exclusion of cardiac etiology 
was later questioned. PCWP can fluctuate with fluid resuscitation and can remain high, 
above 18mmHg, in the absence of heart failure.33 Frequent oscillation of PCWP values 
paired with high interobserver variability in interpretation of tracings, no benefit in 
mortality and increased catheter related complications using pulmonary artery catheter 
(PAC)-guided therapy compared to the use of central venous catheter (CVC)-guided 
therapy led to the removal of this mandate in the criteria.34,35,34  
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The AECC criteria demonstrated weak diagnostic accuracy on autopsy when 
compared to the gold standard pathological hallmark of ARDS, DAD. On autopsy, DAD 
was documented in only 30.4% of those who met the AECC criteria and only 47.6% of 
patients with DAD had a diagnosis of ARDS. From this study, the sensitivity and 
specificity of the AECC criteria were found to be 0.83 and 0.51, respectively.36 Another 
study comparing the AECC criteria to autopsy had similar findings with a sensitivity and 
specificity of 0.71 and 0.67, respectively, and a PPV of 50% and NPV of 83%.37  
The Berlin definition was created in 2012 to standardize the definition of ARDS 
with improved reliability and validity.2 The Berlin definition clarified the existing 
criteria, removed unnecessary measurements, and retained a compatible definition to 
continue incorporating the results of previous clinical trials using the AECC criteria.28 













Table 2. The Berlin Definition Criteria to Diagnose ARDS Introduced in 2012 
Timing Within 1 week of a known clinical insult or new or 
worsening respiratory symptoms 2 
Chest Imaging Bilateral opacities on chest radiograph or CT not fully 
explained by effusions, lobar lung collapse, or nodules2 
Origin of Edema Not fully explained by cardiac failure or fluid overload 
with objective assessment (e.g. echocardiography) to 
exclude hydrostatic edema if no risk factor present 2 
Oxygenation Mild: 200mmHg PaO2/FiO2 <300mmHg with PEEP or 
CPAP ≥ 5 cm H2O 
Moderate: 100mmHg < PaO2/FiO2 < 200 mmHg with 
PEEP or CPAP ≥5cm H2O 
Severe: PaO2/FiO2 < 100 mmHg with PEEP or CPAP 
≥5cm H2O2 
 
 The Berlin criteria established a definitive time frame for the onset of ARDS, 
provided a more explicit definition of bilateral opacities on imaging, and incorporated the 
use of CT.2 The use of CT had a strong association with the detection of EVLW, a 
marker of pulmonary edema, when compared to the gold standard gravimetric 
measurement in sheep studies and the gold standard in vivo technique using 
thermodilution.38,39,40  
 The Berlin criteria also removed PCWP to rule out heart failure due to decreasing 
use of the right heart catheterization after a study found limited reliability, benefit, and 
increased mortality in the setting of diagnosing ARDS.34,35,40 They incorporated the use 
of PEEP, believing the pros of improving Ventilation/Perfusion (V/Q) mismatching and 
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intrapulmonary shunt fraction 41 outweighed the cons of underdiagnosis in resource-
constrained settings with limited access to mechanical ventilators.27 Since its 
introduction, the Berlin diagnostic accuracy has also been questioned. Autopsy findings 
demonstrated a sensitivity of 89% and specificity of 63% with DAD found only in 45% 
of patients diagnosed with ARDS, comparable to the autopsy findings for AECC.42,36,37 
The relative inaccuracy of the Berlin definition compared to the pathologic hallmark, 
DAD, suggests a need for a new definition with improved diagnostic accuracy. 
 
Treatment 
Supportive therapy and correction of the underlying precipitants of ARDS are the  
cornerstones for management with strategies including: (1) Protective Lung Ventilation 
using lower Tidal Volumes (TV); (2) Optimal PEEP management; (3) Optimal PEEP 
Using Esophageal Probe; (4) Prone positioning; and (5) Fluid management.43  
Protective Lung Ventilation 
Supportive therapy focuses on appropriate management of the underlying 
condition and prevention of the propagation of lung injury. The only therapy with proven 
benefit across all severities of ARDS is the protective lung ventilation strategy.1 The 
ARDSnet ARMA trial, which compared higher to lower tidal volume ventilation 
strategies, demonstrated an improvement in mortality.44 This trial marked the importance 
of iatrogenic ventilator induced lung injury in patients with ARDS who are particularly 
susceptible to regional overdistension.45 The lung protective ventilation strategy results in 
the reduction in a number of mechanisms believed to cause lung injury, including: (1) 
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volutrauma, lung injury associated with high volume and lung stretching; 46 (2) 
atelectrauma, lung injury associated with repetitive opening and closing of alveoli;47,48 
and (3) biotrauma, the release of proinflammatory mediators with the potential to initiate 
and propagate local or systemic inflammation that can lead to pulmonary fibrosis.49,50  
 The American Thoracic Society, European Society of Intensive Care Medicine, 
and Society of Critical Care Medicine conducted systematic reviews and meta analyses 
on ARDS management strategies and published evidence-based clinical guidelines for the 
management of ARDS published in May 2017.51 There was agreement for clinical 
therapy across all ARDS groups with a low tidal volume (TV) (4-8mL/kg) based on 
predicted body weight and lower inspiratory pressures (plateau pressure <30cm H2O).51 
These recommendations were established from the ARDSnet ARMA trial published in 
2000 (ARMA trial) comparing the previously used 12 mL/kg TV to 6 mL/kg TV, which 
found a reduction in absolute mortality (39.8% vs. 31.0% p= 0.007).44 As the cornerstone 
of management for patients with all severities of ARDS, it is crucial to be able to 
implement this management therapy early in the course of the disease. 
Optimal PEEP Management 
 Based on the Berlin criteria, a minimum PEEP of 5cmH2O is required for the 
diagnosis of ARDS. PEEP has been found to have a considerable effect on PaO2/FiO2 
ratios and V/Q mismatch.41 A systematic meta-analysis in 2010 using the data from three 
trials (ALVEOLI, LOVS, EXPRESS) comparing high and low PEEPs with lower TVs 
found that those who met the criteria for ARDS with a higher PEEP had a decreased risk 
of in-hospital mortality (34.1% vs 39.1% p=0.049).52 Therefore, optimal PEEP setting in 
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the management of ARDS can be related to clinical outcome, although this belief is 
controversial and the implementation of PEEP is not universally predictable across all 
patients and severities.27 
Optimal PEEP Using Esophageal Probe 
The variations in intrapleural pressures, fluctuating with a patient’s illness 
severity, body habitus, and intrabdominal pressures, spurred a trial to estimate the 
patient’s lung compliance using their intrapleural and transpulmonary pressure gathered 
from esophageal manometry.53,54,55  Using esophageal manometry, a probe was placed in 
the esophagus to measure intrapleural pressure and adjust the PEEP accordingly.54,53,55 
Although there was a slight trend towards a decreased mortality rate, this difference was 
not significant.1 In the esophageal manometry group, the oxygenation and respiratory 
system compliance improved, maintaining the mean transpulmonary end expiratory 
pressure above zero, minimizing alveolar collapse.55 A larger randomized controlled trial 
RCT using esophageal manometry is currently underway.56   
Prone Positioning 
In a multicenter prospective RCT, patients with moderately severe to severe 
ARDS (defined as: PaO2/FiO2 <150mmHg , FiO2 ≥ 0.6, PEEP ≥ 5cmH2O and TV close 
to 6mL/kg predicted body weight) had a significant decrease in 28 and 90 day mortality 
when placed in a prone position for at least 16 consecutive hours.57 Currently, 
recommendations are for patients with severe ARDS to be placed in the prone position 
for 12 hours a day.51 The function of prone positioning is to improve the V/Q 
mismatching and shunt perfusion, reallocating blood away from less ventilated regions,58 
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which has demonstrated improved oxygenation and lung compliance.59 Prone 
positioning, although not tested in low-income populations, offers a feasible treatment 
strategy in locations with limited access to resources. 
Fluid Management 
In 2006, ARDSnet performed a study examining optimal fluid management in 
patients with ARDS, called the Comparison of Two Fluid-Management Strategies in 
Acute Lung Injury (FACTT trial).60 In the FACTT trial, 1,000 patients with acute lung 
injury were stratified to liberal and conservative fluid management protocols for seven 
days.60 Although there was not a significant difference in mortality, the patients who 
underwent the conservative fluid protocol showed an improvement in their lung injury 
score and oxygenation index, an increase in ventilator-free days, and decreased number 
of days spent in the ICU.60 
 In an attempt to further stratify ARDS patients, retrospective data gathered from 
the 2006 FACTT trial identified subphenotypes bringing more homogeneity to 
subgroups. A hyperinflammatory subphenotype, “Phenotype 2”, was identified.61 It was 
associated with increased mortality, sepsis, vasopressor use, lower serum bicarbonate, 
and higher inflammatory markers, such as IL-6, IL-8, and TNFa, compared to 
“Phenotype 1”.61 A difference in mortality was found based on a given treatment strategy 
between the two groups when comparing high to low PEEP and conservative to liberal 
fluid management.61 An improved response was found for liberal fluid management in 
Phenotype 1 (mortality 18% in fluid-liberal vs. 26% in fluid-conservative). In contrast, 
the investigators found that conservative fluid management in Phenotype 2 resulted in 
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improved mortality (mortality 40% in fluid-conservative vs. 50% in fluid-liberal).62 
Therefore, modified criteria allowing patients in low-income populations to be placed on 
the ARDS spectrum could enable these patients to have access to the optimal fluid 
management appropriate with the identification of these subphenotypes. 
Pharmacologic 
With the high mortality rate with ARDS, many drug therapies have been tested with no 
significant reduction in mortality or delayed progression of disease course. Therapies 
incorporated into clinical trials include inhaled nitric oxide, glucocorticoids, 
ketoconazole, surfactant replacement, statin, albuterol, antioxidants, anticoagulation, 
nonsteroidal anti-inflammatory drugs (NSAIDS), and nebulized heparin.63,64,65,66,67,68 
None of these drug therapies have shown a benefit in mortality or course progression in 
the treatment of ARDS.68 Currently, there are new trials underway examining the use of 
mesenchymal stem cells as therapy for ARDS.69,70 
 
Current Research on ARDS 
The most recent large, international epidemiological study, the LUNGSAFE trial 
examined 29,144 patients in participating ICUs and determined ARDS represented 10.4% 
of all ICU admissions and 23.4% of patients on mechanical ventilation.21 However, while 
the study examined 459 ICUs in 50 countries, the results were skewed towards high and 
upper middle income countries with none of the countries involved classified as low-
income countries based on the World Bank Classification.71,21  The prevalence and 
impact of ARDS in low-income and resource-constrained settings remains difficult to 
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estimate. The lack of knowledge regarding the incidence and mortality of ARDS in low-
income settings suggests a need for modified criteria that can assess the overall impact of 
this syndrome in these settings. Limited access to resources contributes to the lack of 
knowledge regarding the global burden of critical illness, as it makes it difficult to 
conduct the appropriate tests and contributes to a higher short term mortality, leaving a 
smaller time frame to estimate the true prevalence of the disease.72  
 
Epidemiology of ARDS in Developed Countries 
In the studies conducted in the developed world over the past 20 years, there have 
been large discrepancies in the incidence of ARDS reported in varying ICUs. All of the 
studies required patients to be in the ICU and only one Scandinavian study 73 did not 
require intubation, reducing the generalizability of this data to resource poor countries 
with limited access to ICU beds and mechanical ventilation. Recent epidemiological 
studies estimated the prevalence of ARDS to be between 10 to 86.2 cases per 100,000 
person-years.20 Proposed etiologies of this variation include: ICU bed availability 74; 
number of study sites, e.g., single center studies, which suggests differences in population 
risk factors; characteristics in different populations; seasonal variation; variation in 
inclusion/exclusion criteria (one study included patients with comorbidities, another 
included patients with FiO2≥ 40% by mask without invasive ventilation); interobserver 
variability in radiographic interpretations; inaccurate administrative coding; ventilatory 
management; variations in treated incidence; and true decreasing incidence of ARDS 





 The concept of treated incidence was first applied in examining the epidemiology 
of severe sepsis across ICUs. The theory of treated incidence can be applied to the 
epidemiology of other critical illnesses, including ARDS. The incidence of ARDS is a 
measure of those treated for it, which can vary based on ICU bed availability, ICU 
resources, and management of predisposing conditions and risk factors.74 All of the 
epidemiological studies using the AECC or Berlin criteria have been reported only for 
ICU patients and, therefore, ICU bed availability has a large impact on the measured 
incidence of ARDS, regardless of the patient’s clinical status. A study in Uganda 
examining the national ICU bed capacity demonstrated hospital capacity ranged from 2 to 
6 beds in 9 hospitals and only 33 adult ICU beds were capable of providing mechanical 
ventilation in the entire country.78  
 With the etiologies for ARDS differing based on global region, it may be difficult 
to extrapolate findings across nations. A study in India found the etiologies of ARDS to 
be malaria (27.6%), leptospirosis (20.7%), undiagnosed fever (27.6%), and pneumonia 
(13.8%), which differs from the results of a US study in which the etiologies were severe 
sepsis with suspected pulmonary etiology (46%) and severe sepsis with suspected non-
pulmonary etiology (33%).22,75 With the differing etiologies based on global region, 
current clinical trials have examined the success of specific treatment strategies in only a 
subset of patients whose etiologies of ARDS reflected the higher income nations. This 
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highlights the need for the inclusion of all patients with ARDS in clinical trials, 
regardless of global region, as varying etiologies may contribute to different outcomes. 
 The Global Burden of Disease study analyzed data gathered between 1980 and 
2010. It examined the global distribution and burden of various diseases, health risk 
factors, and injuries worldwide. Although it estimated the incidence of various high yield 
diseases, it failed to estimate the prevalence of ARDS due to the inability of the 
syndrome to fit into only one of the categories used in the study: 1) Communicable, 
neonatal, maternal, nutritional disorders; 2) Noncommunicable; and 3) Injuries.79,20  
 
Kigali Modification Study in Rwanda 
 To bridge the gap between the unknown ARDS epidemiology in low-income 
countries and limited access to resources, Riviello and colleagues examined the incidence 
of ARDS using the Kigali modification, criteria based on the Berlin definition that can be 
applied in resource poor settings (Table 3). The study examined the incidence of ARDS 
using the Kigali modification compared to using the Berlin definition at the University 
Teaching Hospital in Kigali, Rwanda.8 The author highlighted an inability to diagnose 
ARDS based on the Berlin criteria due to limited access to invasive interventions, 
particularly CT scanning, chest radiography, arterial measurements for oxygenation, and 




Revisions Introduced in the Kigali Modification 
 The changes the Kigali modification introduces are the use of SpO2/FiO2≤ 
315mmHg in place of PaO2/FiO2 ratios, the use of lung ultrasound instead of CT in the 
diagnosis of bilateral opacities, and the removal of the PEEP requirement (Table 3).8  
 
Table 3 Berlin Definition vs. Kigali Modification 
 Berlin Criteria Kigali Modification 
Timing Within 1 week of a known clinical 
insult or new or worsening 
respiratory symptoms2 
Within 1 week of a known 
clinical insult or new or 
worsening respiratory 
symptoms8 
Chest Imaging Bilateral opacities not fully 
explained by effusions, lobar/lung 
collapse or nodules by chest 
radiograph or CT2 
Bilateral opacities not fully 
explained by effusions, 
lobar/lung collapse or nodules 




Respiratory failure not fully 
explained by cardiac failure or 
fluid overload (requires objective 
assessment e.g. echocardiogram to 
exclude hydrostatic edema if no 
risk factor present) 2 
Respiratory failure not fully 
explained by cardiac failure or 
fluid overload (requires 
objective assessment e.g. 
echocardiogram to exclude 
hydrostatic edema if no risk 
factor present) 8 
Oxygenation • Mild: 200mmHg< PaO2/FiO2 
<300mmHg 
• Moderate: 100mmHg < 








Minimum 5 cmH2O PEEP 
required by invasive ventilation 
(noninvasive acceptable for mild 
ARDS)2 
No PEEP requirement 
consistent with AECC 
definition8 
ARDS: Acute Respiratory Distress Syndrome 
CT: Computed Tomography 
PEEP: Positive End-Expiratory Pressure 
AECC: American-European Consensus Conference 
 
Evidence of Support of Revisions in the Kigali Modification 
Oxygenation 
 Oxygenation measurements using SpO2/FiO2 have demonstrated significant 
correlation to PaO2/FiO2 values and have been a validated replacement for PaO2 values.80 
Rice et al demonstrated that the SpO2/FiO2 value of 235 resulted in an 85% sensitivity 
and specificity for PaO2/FiO2 ratio of 200 and the SpO2/FiO2 value of 315 had a 
sensitivity and specificity of 91% and 56%, respectively, for a PaO2/FiO2 ratio of 300.80 
Follow up studies further validated this method by showing similar outcome predictions 
when using the SpO2/FiO2 ratio compared to the PaO2/FiO2 ratios in the daily monitoring 
of pulmonary parameters of Sequential Organ Failure Assessment (SOFA) scores.81  
 
Lung Ultrasound 
The use of noninvasive bedside lung ultrasound has shown promise in assisting in 
the diagnosis of ARDS. Using lung ultrasound, ARDS presents with characteristic lung 
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profiles defined by Lichtenstein and colleagues.82,4 It has demonstrated a strong 
diagnostic accuracy with 93%, 97%, and 95% for pleural effusion, alveolar consolidation 
and alveolar-interstitial syndrome respectively, a promising improvement from chest 
radiography and auscultation.32 In 2008, Lichtenstein and colleagues developed different 
characteristic lung profiles for various pulmonary pathologies and examined the use of 
lung ultrasound in aiding in the diagnosis of ARDS.4 Lung ultrasound had a strong 
diagnostic accuracy with 97% sensitivity and 95% specificity using the lung profiles 
associated with various pulmonary pathologies.4 The BLUE protocol was developed as a 
stepwise algorithm that could be used bedside to examine the pulmonary function of a 
given patient.4 It examines 12 zones on the chest, evaluating the presence or absence of A 
or B lines, lung sliding, alveolar consolidation and/or pleural effusion.4 The findings are 
categorized into different lung profiles. ARDS is associated with multiple profiles.4 
 One study demonstrated promising findings in using lung ultrasound to examine 
extravascular lung water (EVLW), the fluid extravasated out of the pulmonary 
vasculature referred to as pulmonary edema, an independent risk factor for ARDS.83 
 Bass and colleagues compared the use of lung ultrasound combined with pulse 
oximetry (SpO2) to the use of chest radiography combined with arterial blood gas 
(PaO2/FiO2) in diagnosing ARDS. They found a sensitivity of 83% and specificity of 
62% for moderate to severe ARDS. They demonstrated SpO2/FiO2 ≤ 315 is sensitive for 
PaO2/FiO2≤300 and SpO2/FiO2 ≤235 is specific for PaO2/FiO2 ≤200.84 This study showed 
a reduced ultrasound accuracy compared to the previous studies mentioned with evidence 
of decreased sensitivity for consolidation.84 One possible explanation for the decreased 
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diagnostic accuracy was their use of an algorithm other than the validated BLUE 
protocol.  
 Overall, the incorporation of lung ultrasound in place of CT is a validated, 
feasible approach for diagnosing ARDS with high diagnostic accuracy and correlation to 
EVLW. The development of the BLUE protocol will allow for doctors of patients in 
resource poor settings to utilize a validated, stepwise approach to the diagnosis of ARDS 
using lung ultrasound, leaving less room for interobserver variability. 
 
Removal of PEEP 
 Although PEEP has an impact on the PaO2/FiO2 ratio, it is not feasible in low-
resource settings and thus, the last modification in the Kigali criteria was its removal. In 
the Kigali study, the hospital had access to 6 ventilators that were all reserved for 
mechanically ventilated patients. Therefore, noninvasive ventilation, which also required 
the use of a mechanical ventilator, was not available.8 The application of a minimum 
level of PEEP (5 cm H2O) can have a dramatic effect on the PaO2/FiO2 ratio, total shunt 
fraction, and V/Q mismatch that can improve the patient’s PaO2/FiO2 ratio beyond the 
point where they meet criteria for ARDS.41,2 Therefore, the elimination of PEEP may 
overestimate the number who would meet the criteria if PEEP were applied. However, 
the effect of PEEP is not universally predictable and the authors of the AECC criteria 





Estimate of ARDS Incidence Using the Modified Kigali and Berlin Criteria 
The Kigali study by Riviello and colleagues was a six-week prospective 
observational study examining the primary outcome of hospital incidence of ARDS using 
the Kigali modification compared to the Berlin definition. In comparison to prior ARDS 
epidemiological studies, all adult patients admitted to the hospital were screened for 
hypoxemia (SpO2< 90% or receiving supplemental oxygen) every day, which resulted in 
a 12% incidence (126/1046) of hypoxemia over the course of the study period. Using the 
Kigali modification, 4% (42/1046) screened positive for ARDS with a mortality rate of 
50%, while 0% fulfilled the criteria for the Berlin definition due to lack of access to 
arterial samples and mechanical ventilation. The most common etiologies for ARDS were 
infections (44.1%, of which 10% were tuberculosis), trauma (29.4%) and surgery (25%). 
Only 21/42 patients were admitted to the ICU. Using two of the Kigali criteria and adding 
the requirement for a chest radiograph decreased the hospital incidence from 4% to only 
1.6% because less than half of the patients with hypoxemia ever had a chest radiograph. 
The results of this study suggest a need for a validated, modified criteria for diagnosis of 
ARDS in resource-poor settings.8 
 
Limitations 
There are many limitations to this study. They include that it was a single center 
study with low generalizability for the rest of Africa given Rwanda’s relatively low HIV 
rate.8 Additionally, it had a less restrictive referral protocol, making the population 
incidence difficult to predict and possibly included those with cardiogenic pulmonary 
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edema, leading to a decreased accuracy in the estimated incidence of ARDS.8 However, 
the most important limitation to this study was the unknown validity of the Kigali 
modification as a whole.8  
 
Study Examining External Confirmation of Kigali Modification in the Netherlands 
 
Vercesi and colleagues performed a single center observational study in the 
Netherlands to examine the external confirmation of the Kigali modification for moderate 
to severe ARDS in invasively mechanically ventilated patients. They performed four 
separate analyses: (1) Kigali vs. Berlin criteria; (2) Kigali vs. Berlin with lung CT as 
confirmation; (3) Kigali using PaO2/FiO2 instead of SpO2/FiO2 vs. Berlin; and (4) Kigali 
with a stricter LUS criteria vs. Berlin. They found the Kigali modification had a high 
sensitivity for ARDS but a moderate specificity. The specificity was increased when 
substituting PaO2/FiO2 for SpO2/FiO2 with a sensitivity of 0.96 and specificity of 0.86.10 
They found the best accuracy using stricter LUS criteria, improving the specificity to 
0.93.10 The overdiagnosis of ARDS was largely attributed to the use of LUS and using a 
stricter LUS criteria improved the ability of this criterion to differentiate ARDS.10 One of 
the main limitations in this study was the inability to generalize to nonventilated patients, 
which is crucial for patients in resource-poor settings, like large hospitals having limited 
access to mechanical ventilators.10 This study was also completed in a single center with 
a relatively small sample size that had moderate or severe ARDS 10 compared to the 




Noninvasive Measurement to Rule Out Cardiogenic Pulmonary Edema 
 
One of the recognized major limitations in the Riviello and colleagues Kigali 
modification is the possible inclusion of cardiogenic pulmonary edema. The authors ruled 
out cardiogenic pulmonary edema contributions either by a history of congestive heart 
failure, myocardial infarction (MI) in the chart, or bedside ECHO examining valvular 
pathology.8 They failed to specify if any other objective measurements were used to rule 
out heart failure on ECHO besides the presence of valvular pathology.8  
In the AECC criteria, PCWP was directly measured to rule out left heart 
pathology as a potential confounding factor but was later removed from the criteria due to 
the high degree of invasiveness in obtaining the measurements. Echocardiography has 
demonstrated promising results in evaluating elevated filling pressures by estimating 
mitral inflow signals and observing differences in pressures in the left atrium (LA) and 
left ventricle (LV) during diastole to predict elevated PCWP noninvasively.85,86 Table 4 
describes the ECHO Terminology used in the American Society of Echocardiography 










Table 4. ECHO Terminology Used in the 2016 ASE Protocol 
ECHO 
Terminology 
Definition Clinical Correlation 
Mitral E wave 
velocity 
Inflow signal from the 
LA to the LV in early 
diastole 87 
 
-The E wave reflects the pressure 
gradient between the LA and the LV. In 
early diastolic dysfunction, as the LV 
pressure increases, the pressure gradient 
shifts causing elevated LV pressure 
relative to LA pressure, and the E wave 
decreases. As diastolic dysfunction 
progresses, the LA pressure increases to 
overcome the LV pressure, and the E 
wave increases relative to the A wave88 
Mitral A wave 
velocity 
Inflow signal in late 
diastole including the 
time of atrial contraction 
87 
-In early diastolic dysfunction, the heart 
relies on atrial contraction for LV 
filling, causing the A wave to increase. 
In later diastolic dysfunction, LA 
pressure increases to compensate for 
elevated LV pressure. This causes an 
increased inflow in early diastole (E 










Ratio of inflow signal in 
early diastole over late 
diastole 87 
-In early diastolic dysfunction, E/A 
ratio is decreased due to increased late 
diastolic filling reflecting atrial 
compensation. In late diastolic 
dysfunction, as the LA pressure 
increases and LV relaxation capacity 
decreases, the E/A ratio will continue 
increase.88,87 
-Increased values reflect increased 
diastolic dysfunction87,89 
E’ -Measurement of LV 
relaxation in early 
diastole 87,89 
-Inversely correlated 
with early diastolic 
pressure 87,89 
-Can be measured from 
septal or lateral annulus 
89 
-Doppler measurement that is a marker 
of LV relaxation and is inversely 
related to LA pressure 
-Decreased values reflect increased 
diastolic dysfunction87,89 




-Increased ratio suggests increased 
mitral inflow relative to left ventricular 
relaxation 87,89 











increased LV filling 
pressures87,89 
Increased values reflect increased left 
sided filling pressures87 
 
The ASE has presented guidelines used in estimating left ventricular filling 
pressures by echocardiography for both preserved and depressed ejection fraction (EF). 
EF is the fraction of blood ejected from the heart during systole, estimated by the volume 
of blood in the left ventricle immediately before and after systole, expressed as a 
percentage.87  In patients with normal EF, they use E/e’, Septal e’ velocity, TR velocity 
and LA volume index to evaluate the diastolic dysfunction. 87,5 In patients with reduced 
EF, they used Mitral E/A ratio followed by E/e’, TR velocity and LA volume index to 
estimate LV filling pressures.87 The European Association of Cardiovascular Imaging 
(EACVI) and ASE released the first recommendations in 2009 and later modified them to 
a simpler version in 2016.5 In 2017, Lancellotti and colleagues published the Euro-Filling 
study comparing the diagnostic accuracy of the 2009 and 2016 algorithms for predicting 
left ventricular filling pressure (LVFP) when compared to the invasive left heart 
catheterization.5,90 They found an improvement in the diagnostic accuracy based on the 
2016 recommendations and concluded that noninvasive estimation of LVFP can be 
mildly reliable and useful in a clinical setting.90  
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There are different types of filling patterns based on the grade of diastolic 
dysfunction. The spectrum extends from normal, to impaired relaxation, to 
“pseudonormal” filling, then to restrictive filling patterns.87 
The ASE protocol is an algorithm that first separates patients based on EF.87 In 
patients with a normal EF, if they have greater than two of the four criteria (Average E/e’ 
> 14; Septal e’ velocity < 7cm/s or Lateral e’ velocity < 10cm/s; TR velocity> 2.8m/s; or 
LA volume index > 34ml/m2), they are defined as having diastolic dysfunction with 
preserved EF.87 If they have two of the four criteria, they are indeterminate, less than two 
they have normal diastolic function.87  
In patients with reduced EF and patients with myocardial disease and normal EF, 
the algorithm starts with mitral inflow.87 If the E/A ≤ 0.8 + E ≤ 50cm/s then the patient is 
noted to have a normal left atrial pressure (LAP).87 If the E/A ≥ 2, then the patient is 
noted to have an increased LAP with Grade III Diastolic Dysfunction.87 If the E/A ≤ 0.8 
+ E >50cm/s or E/A >0.8 < 2 then three follow up criteria are measured (average E/e’ 
>14; TR velocity > 2.8 m/s, LA Volume index > 34ml/m2).87 If at least two of the three 
are negative, the patient is considered to have a normal LAP with Grade I Diastolic 
Dysfunction.87 When at least two of the three criteria are positive, the patient is 
considered to have an increased LAP with Grade II Diastolic Dysfunction.87 
 Sugimoto and colleagues examined diastolic annular and mitral inflow velocities 
in estimating PCWP in patients with both systolic dysfunction, demonstrated by reduced 
EF, and diastolic dysfunction, demonstrated by preserved EF.86 They evaluated 165 
patients using echocardiographic examination to estimate PCWP >18mmHg confirmed 
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on right heart catheterization.86 They demonstrated a high correlation of mean PCWP and 
E/A ratio.86 When using E’≤ 8 and E/A ≥ 1.81 in the preserved ejection fraction (EF) 
group, they found a diagnostic accuracy of 94.0%, sensitivity of 87.5%, specificity of 
94.7%, positive predictive value (PPV) of 63.6% and negative predictive value (NPV) of 
98.6%.86 When using E’ ≤ 8 and E/A ≥ 1.16 in the reduced EF groups, they found a 
diagnostic accuracy of 89%, sensitivity of 84.9%, PPV of 77.8%, and NPV of 97.8%.86 
Overall, it was found that, after they account for EF, using E’<8 and E/A, had high 
diagnostic accuracy of predicting PCWP >18mmHg compared with E/E’ derived 
estimations.86  
 Dokainish and colleagues examined noninvasive ECHO assessment of filling 
pressures compared with B-type natriuretic peptide (BNP), a hormone that has been 
found to correlate with ventricular stress and elevated left ventricular filling pressures, in 
estimating PCWP.85 They found, when comparing the two noninvasive techniques, BNP 
and ECHO, ECHO measurements using E/Ea had a stronger association with PCWP 
>15mmHg.85 They further subcategorized their patients based on EF with EF>50% and 
EF<50%.85 They found with ECHO had a higher specificity for PCWP >15mmHg in 
patients with reduced EF compared to BNP.85   
To summarize, noninvasive measurements of LVFP can be used in addition to the 
previously used measurements in the Kigali criteria, including evidence of valvular 
pathology on ECHO, history of heart failure and myocardial infarction (MI) with 




Timing of Onset of ARDS and Clinical Outcome 
The timing of the presentation of ARDS can be crucial in the clinical outcome for 
the patient. One prospective multicenter study compared early (<48 hours) to late (>48 
hours) onset of ARDS after admission to the hospital.11 They found a higher in-hospital 
mortality rate and longer durations in ICU and mechanical ventilation in those who were 
diagnosed with late onset ARDS.11 Another study examined 393 patients across 198 
ICUs in 24 European countries, where 64.6% presented with early onset ARDS (within 
48 hours ICU admission) and 35.5% had late onset ARDS (>48 hours after ICU 
admission). Although no difference in mortality was found between the two groups in 
this study, there was a statistically significant increase in ICU and hospital length of stay 
for late onset ARDS.91 Another study performed a secondary class analysis on the two 
subphenotypes in ARDS from two randomized controlled trials (RCTs) and found class 
2, the hyperinflammatory subphenotype, had progressive organ failure by day 3.61 
Although there have been studies comparing early and late onset ARDS using the Berlin 
criteria, there have not been any studies examining the time to diagnosis from arrival to 
the Emergency Department (ED) with the Berlin criteria compared to the noninvasive 
modified Kigali definition. Using noninvasive measures in the Kigali criteria to diagnose 
ARDS compared with the use of invasive tools in the Berlin criteria could lead to a more 
expeditious diagnosis of ARDS by allowing all the diagnostic tests to be performed at the 
bedside. This could decrease the time between onset and treatment, including 
noninvasive ventilation, protective lung ventilation, ECMO, and/or triage to an institution 
capable of these interventions.3 
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Many studies have examined the effect of timing in the use of ECMO in ARDS.15 
One single center retrospective study examined the early initiation of ECMO for patients 
with severe ARDS and found an improved mortality for early introduction of ECMO 
compared to conventional therapy with protective mechanical ventilation.15 In this study, 
the average time to ECMO intervention after the diagnosis of severe ARDS was 1.9 +/- 
1.4 days.92 
A RCT in West China compared two ventilation strategies on patients diagnosed 
with ARDS who were on mechanical ventilation <48 hours total.14 They compared the 
gold standard lung protective ventilation strategy with the airway pressure release 
ventilation (APRV) method.14 The results showed that early administration of APRV led 
to a decreased length of mechanical ventilation, ICU stay, and an improvement in 
oxygenation and respiratory system compliance with decreased plateau pressure.14  
Multiple studies have shown that early incorporation of noninvasive ventilation 
(NIV), such as CPAP, in patients with ARDS can allow them to avoid invasive 
mechanical ventilation (IMV).21 The LUNG SAFE study examined the epidemiology of 
ARDS across 50 countries and found, of those treated with NIV on days 1 and 2 of ICU 
admission, 65% were able to avoid IMV.93,21 
To summarize, the use of noninvasive technologies in the Kigali modification 
could enable early diagnosis of ARDS, allowing earlier allocation to the correct therapies, 
including NIV, protective ventilation, APRV, ECMO, and optimal approaches to fluid 
management, which are critical to delaying disease progression and/or reducing mortality 
in patients with ARDS. There is a lack of data comparing the time of onset of ARDS 
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using the Berlin criteria to the noninvasive Kigali modification beginning from the arrival 
to the emergency department, which would assist in outlining the optimal time to 






This will be a multi-center observational study comparing timing to diagnosis of ARDS 
using the Kigali modification and the Berlin criteria and calculating the diagnostic 
accuracy, including the sensitivity, specificity, positive predictive value and negative 
predictive value, of the Kigali modification using the Berlin definition as the gold 
standard.92 
Study population and sampling 
The study population will include patients presenting to the Boston Medical 
Center, Brigham and Women’s Hospital, Massachusetts General Hospital, Beth Israel 
Deaconess Medical Center, Tufts Medical Center, Lahey Medical Center and St. 
Elizabeth Medical Center Emergency Departments with hypoxemia (SpO2 < 90%). The 
patients will be recruited over a 12-month period. Inclusion and exclusion criteria are 
detailed below (Table 5). Patients will be classified as mild, moderate, or severe ARDS 
based on the appropriate SpO2/FiO2 ratio in the Kigali modification and the PaO2/FiO2 
ratio in the Berlin definition.  
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Table 5. Inclusion and Exclusion Criteria for Study Patients 
Inclusion Exclusion 
1. All patients over the age of 18 and 
personally able or legal next of 
kin are able to provide informed 
consent 
2. All patients will have hypoxemia 
<90% on presentation 
3. SpO2 <90% and/or receiving 
supplemental oxygen 
4. All patients will have timing of 
onset of illness <7days prior to 
presentation 
1. Any patients with elevated filling 
pressures based on ASE protocol 
using echocardiography or clinical 
evidence volume overload 
 
A previous IRB submission to Boston Medical Center estimated the number of patients 
diagnosed with ARDS at Boston Medical Center annually to be 50. The estimated sample 
size in this study will be 350 based on the previous estimation of 50 from Boston Medical 
Center, multiplied by the seven facilities involved. Based on this sample size of 350, the 
minimum delectable effect size in mean time to diagnosis by a paired T test will be 0.150, 
which translates to a small effect size based on the Cohen’s effect size measurements.94 
This was calculated using an alpha of 0.05, a beta of 0.2, and a standard deviation of 1.  
Study variables and measures 
Demographic data collected will include age, gender, disease severity based on the Acute 
Physiology and Chronic Evaluation (APACHE) II score, comorbidities (i.e. neurological, 
cardiac, respiratory, gastrointestinal, renal, hematologic, infectious disease), patient 
category, i.e., medical or surgical, and potential cause for ARDS.10 
The study’s primary endpoint will be the time from the patient’s presentation to 
the ED to the time to diagnosis of mild, moderate, and severe ARDS based on the 
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modified Kigali criteria compared to the Berlin definition. The secondary endpoint will 
be the diagnostic accuracy of the Kigali modification when using the Berlin criteria as the 
gold standard reference.  
All patients presenting to the institutions’ Emergency Departments with 
hypoxemia (SpO2 < 90%) and/or on supplemental oxygen will be screened for ARDS 
using the Kigali modification and the Berlin criteria (Figure 1). If the patients meet the 
timing (< 7 days) and oxygenation criteria based on the Kigali modification (SpO2/FiO2< 
315) and/or Berlin definition (PaO2/FiO2 ≤300), the patients will have a cardiac echo 
performed by an ECHO technician to rule out a cardiac etiology for the pulmonary 
edema. After ruling out a cardiac etiology, lung ultrasound profiles and chest radiographs 
or CT will be obtained. Lung ultrasound images will be obtained and interpreted by a 
pulmonary physician blind to the study. Two separate panels of intensivists will examine 
the data including the SpO2/FiO2, the PaO2/FiO2, chest radiograph or CT, and the 
interpretations of the lung ultrasounds and echocardiograms reported by the screening 
physicians. If the patients in the study do not meet the criteria of ARDS, they will be 
continued to be screened every 12 hours during their admission to evaluate for delayed 
onset of presentation. If the patients in the study meet the criteria of ARDS for one and 
not the other, they will be continued to be screened with the other criteria every 12 hours. 
For example, if they meet the Berlin criteria and not the Kigali criteria, they will continue 
to be screened with the Kigali criteria every 12 hours during their admission. If they meet 
the Kigali criteria and not the Berlin criteria, they would continue to be screened for the 




Figure 1. Steps in the proposed study comparing the time to diagnosis of the Kigali 




The interpreting physicians will be randomized into two groups. Physicians in Groups 1 
will evaluate the data based upon the modified Kigali criteria and physicians in Group 2 
will analyze the data using the Berlin criteria.  
 Physicians will determine an ARDS diagnosis based on the Kigali modification if: 
(1) the patient presents <7 days from onset or worsening symptoms; (2) SpO2/FiO2< 315; 
(3) negative cardiac etiology based on ASE protocol, and/or without valvular pathology, 
and/or 2 signs and symptoms of heart failure with a history of MI or heart failure; and (4) 
positive lung ultrasound (i.e., see Lung Ultrasound protocol).  
 Physicians will determine an ARDS diagnosis based on the Berlin definition if: 
(1) the patient presents < 7 days from onset or worsening symptoms; (2) PaO2/FiO2< 300; 
(3) respiratory failure not fully explained by cardiac etiology with objective assessment 
e.g., ECHO; (4) positive bilateral opacities on either chest radiograph or CT; and (5) 
minimum PEEP 5 mmHg.  
 
Lung Ultrasound protocol 
The Lung Ultrasound protocol will be the stricter LUS protocol applied in the external 
confirmation Vercesi et al study, completed in the Netherlands (Table 6).10 The LUS 







Table 6. Strict Lung Ultrasound Protocol Used in the Vercesi Study Examining the 
External Confirmation of the Kigali Modification in the Netherlands 
Lung Ultrasound Protocol  
Positive Finding either: 
a. At least 2 fields per hemithorax scored as B2 or C*10 
b. At least 3 fields per hemithorax scored as B1 or greater*10 
§ If one lung zone has multiple patterns, it will be scored as the most severe pattern10 
§ Order severity: C>B2>B1>A10 
 
Table 7. BLUE Profiles Used in the Strict Lung Ultrasound Protocol Developed by 
Vercesi and Colleagues When They Examined the External Confirmation of the Kigali 
Modification in the Netherlands 
Blue Profiles 
Lung Profile View on Ultrasound Correlated Syndromes 
A  § Predominant A lines with lung 
sliding at anterior surface in supine 






§ Status Asthmaticus 
§ Pneumonia 4 
B  § Anterior predominant B lines also 
referred to as Anterior Interstitial 
Syndrome with Lung Sliding 
§ Cardiogenic 
Pulmonary Edema 
§ Pneumonia 4 
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§ B lines suggest juxtaposition of 
matter with different densities and 
echogenicity such as fluid and air 4 
§ 3 or more B lines in single view 
are called B+ lines4 
 
A/B § Anterior predominant A lines in 
one hemithorax and anterior 
predominant B lines on other 
hemithorax 4 
§ Pneumonia4 
C § Anterior Consolidation 4 § Pneumonia4 
 
Lung Ultrasound Steps 
Two clinicians trained in lung ultrasound blinded to the study will perform and interpret 
the lung ultrasound bedside. If two clinicians disagree, the results will be counted as 
interobserver variability and excluded from the analysis. Left and right chest walls will be 
subdivided into 6 regions on each side equaling 12 total regions based on the BLUE 
protocol.4,10 The lines used to make the 12 lung zones will be the parasternal, 
paravertebral, anterior axillary, posterior axillary lines and a transverse line separating 
them into top and bottom segments.10 The 12 lung regions will be scanned using a 5-MHz 
microconvex probe, scored by the screening physicians, and will be classified as patterns 
based on various lung ultrasound profiles defined in the BLUE protocol (Table 7) and 
will be separated into A, B and C patterns based on the Vercesi strict lung ultrasound 
protocol (Table 6).10,4 The “A pattern” is defined as mainly A lines with lung sliding and 
less than 3 B lines.104 A lines are horizontal lines that arise from the pleural line that 
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coincide with well aerated lung tissue.10,4 The “B pattern” refers to 3 or more B lines with 
lung sliding.10,4 B lines are vertical lines that appear like a “comet tail” and extend from 
the pleural line to end of the screen.4,10 The B pattern is subdivided into B1 and B2, with 
the B1 pattern defined as 3 or more spaced out B lines with lung sliding.10,4 The B2 
pattern is defined as 3 or more B lines.10 A “C pattern” has a tissue-like appearance with 
low echogenicity consistent with a consolidation.10,4 Pleural effusions will be defined as 
detection of pleural fluid in 3 out of 6 regions in the hemithorax.10 Because the 
neighboring lung can have atelectasis secondary to the effusion, these regions will be 
excluded.10  
 
American Society Echocardiography Protocol 
To exclude cases of pulmonary edema fully explained by cardiac etiology, the ASE 
protocol to estimate elevated left sided filling pressures in both preserved and reduced EF 
will be used in addition to presence of valvular pathology on ECHO and history of MI or 
heart failure in the chart with 2 or more signs and symptoms of volume overload (i.e. 
dyspnea, jugular venous distension, pitting edema). These symptoms of volume overload 
have a high specificity for congestion.95,96 Table 8 outlines the criteria that qualify for a 







Table 8. Criteria to Evaluate for Cardiac Etiology in the Kigali Modification in the 
Proposed Study 
Positive Cardiac Etiology if at least one of the following: 
§ Presence of diastolic dysfunction based on ASE algorithm using tissue doppler 
and 2D ECHO 
§ Presence of valvular pathology on ECHO 
§ History of heart failure or MI in chart and 2 of the following: 
§ Dyspnea 
§ Jugular venous distension 
§ Pitting edema 
 
Recruitment 
Patients presenting to the Emergency Department in Boston Medical Center, Brigham 
and Women’s Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical 
Center, Tufts Medical Center, Lahey Medical Center and St. Elizabeth Medical Center 
Emergency Departments with SpO2 < 90% and/or on supplemental oxygen will be 
approached by the Research Assistant and asked for consent to participate in the study. If 
patients are not able to provide consent, the legal next of kin will be asked. 
 
Data collection 
The necessary data will be taken from the Electronic Medical Record and paper charts 
and recorded into a data spreadsheet in Excel. The data that is not included in the 
standard of care will be separately entered into the data spreadsheet in Excel by the 
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research assistant at the given facility. The data will be collected in a secure manner with 
protected health information (PHI) kept confidential and not used in the study. The data 
will be stored on a HIPAA compliant computer with confidentiality maintained 
throughout the entire study. 
 
Data analysis 
Categorical variables, including demographics, comorbidities, patient category 
(medical vs. surgical), and likely etiology of ARDS will be expressed as counts and 
percentages. 
The primary outcome of the time to diagnosis of ARDS by the Berlin and Kigali 
criteria will be compared using a paired t test. 
Diagnostic accuracy of the Kigali modification will be analyzed using the Berlin 
definition as a gold standard reference. Sensitivity, specificity, positive predictive value 
and negative predictive values will be calculated as percentages with 95% Confidence 
Intervals.  
Timeline and resources 
The study will take place from Fall 2019 to March 2021 (Table 9). 
 
Table 9: Proposed Study Timeline 
 
Fall 2019 IRB Submission and Application and 
Approval 
January 2020-January 2021 Patient Recruitment 
 






Resources involved will be the funding required for the additional tests and 
interpretations involved in diagnosing ARDS with the Kigali criteria. It will also include 
the salaries of the investigators in the seven emergency departments in the Boston area, 
the research assistants doing hospital recruitment and the salary of one statistician 
performing the data analysis. Additionally, it will involve compensating the screeners 
involved in interpreting the lung ultrasound and echocardiography and the physicians 
making the diagnosis of ARDS. 
Institutional Review Board 
The recruitment and study protocols will be submitted for review to the Institutional 
Review Board (IRB) at the Boston University Medical Campus through the expedited 
common rule group 4, the section on collection of data through noninvasive procedures, 







The results of this study will help determine the diagnostic accuracy of the Kigali 
modification using the Berlin criteria as the gold standard and whether the Kigali 
modification diagnoses ARDS earlier than the Berlin criteria. The timing to the diagnosis 
of patients presenting to the ED using the Berlin criteria alone and the Berlin criteria 
compared to the Kigali modification is not well studied. Measuring the timing to 
diagnosis will shed light on the clinical course that leads to the development of ARDS 
and potentially allow for earlier access to proper therapeutic intervention. Although there 
have been studies evaluating the timing of ARDS and prognostic outcome on arrival to 
ICU or on admission, there is a lack of research in examining time to presentation to the 
ED, which can be applied to lower income populations as hospital bed capacity is limited.  
The outline of this study does have limitations. Because there are two groups of 
physicians evaluating one criteria, either the Kigali or Berlin, this could introduce bias 
into the study. However, given both the Kigali criteria and Berlin criteria are relatively 
objective and the imaging, including the echocardiography and the lung ultrasound, will 
be interpreted by separate physicians, the bias will be limited. Another limitation involves 
the location of the study. Given these medical centers are in the Northeastern region of 
the United States, most patients will be from the local area. Therefore, the study lacks 
generalizability to lower income settings like Rwanda. In addition, the 2016 ASE 
protocol, examining left sided filling pressures, was less reliable when compared to the 
direct measurement of the left heart catheterization in the EACVI Euro-filling study, 
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which demonstrated a sensitivity of 43% and a specificity of 75%.90 The decreased 
sensitivity may be improved by providing the patient’s clinical context, including the 
signs and symptoms of volume overload and valvular pathology, as was done in the 
original Kigali study. The exclusion of PEEP will likely overestimate the prevalence of 
ARDS by including patients who would not meet the ARDS criteria if a minimum PEEP 
of 5cmH2O were applied. However, excluding PEEP will allow for the study population 
to be representative of low-income populations. Lastly, although lung ultrasound has 
demonstrated high accuracy compared to chest radiograph in diagnosing ARDS, in the 
Vercesi et al study, lung ultrasound overestimated ARDS when compared to CT. Based 
on the Vercesi study, a stricter LUS criteria will be used to increase its specificity.10 
Summary 
In summary, based on the literature review, ARDS is a disease with high mortality, 
inaccurate measures of global epidemiology and limited treatment options that have been 
shown to have benefits on mortality. With the global estimation of ARDS difficult to 
predict in low resource settings, a validated, modified definition using available tools in 
low-income populations will elucidate the epidemiology and etiologies of ARDS in these 
regions. With differing etiologies from high-income countries, low-income populations 
may respond to new treatments differently in clinical trials, leading to a revolution in 
management of ARDS according to its etiology. This novel approach to diagnosing 
ARDS will allow physicians to rapidly screen patients upon presentation to the ED in 
both high- and low-income countries, thereby evaluating the optimal timeline for 
therapeutic interventions in both populations. 
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Using noninvasive tools may lead to an earlier diagnosis of ARDS, allowing 
patients in need sufficient time to relocate to resource-equipped hospitals. The proposed 
study will attempt to address the gaps in the diagnosis and time to therapeutic 
intervention seen in low-income populations using noninvasive tools. 
Clinical and/or public health significance 
The benefits to diagnosing ARDS earlier in the course of the disease include the 
efficacious triage to ECMO, timely institution of protective ventilation management and 
choosing the optimal approach to fluid management based on the subphenotype.44,62,15 
Current research is underway exploring the use of mesenchymal stem cell therapy that 
may demonstrate improved outcomes if introduced earlier in the disease.69,70 
Additionally, patients who suffer from ARDS in low-income populations will be 
correctly diagnosed, potentially triaged to a higher level of care, and perhaps incorporated 
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